Zacks: Analysts Expect Intersect ENT Inc (XENT) Will Announce Earnings of -$0.20 Per Share
Equities analysts expect Intersect ENT Inc (NASDAQ:XENT) to announce earnings of ($0.20) per share for the current quarter, Zacks reports. Six analysts have provided estimates for Intersect ENT’s earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.26). Intersect ENT posted earnings per share of ($0.22) during the same quarter last year, which suggests a positive year over year growth rate of 9.1%. The company is expected to issue its next quarterly earnings report on Wednesday, November 1st.
On average, analysts expect that Intersect ENT will report full-year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.70) to ($0.48). For the next year, analysts forecast that the business will report earnings of ($0.36) per share, with EPS estimates ranging from ($0.48) to ($0.23). Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Intersect ENT.
Intersect ENT (NASDAQ:XENT) last released its quarterly earnings data on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.19) by $0.11. The firm had revenue of $24.00 million for the quarter, compared to analyst estimates of $22.62 million. Intersect ENT had a negative net margin of 9.46% and a negative return on equity of 8.15%. The company’s revenue for the quarter was up 24.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.21) EPS.
Several analysts have commented on the stock. Zacks Investment Research upgraded shares of Intersect ENT from a “hold” rating to a “buy” rating and set a $33.00 target price on the stock in a report on Thursday. TheStreet upgraded shares of Intersect ENT from a “d” rating to a “c-” rating in a report on Tuesday, August 1st. BidaskClub downgraded shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Deutsche Bank AG set a $31.00 target price on shares of Intersect ENT and gave the stock a “buy” rating in a report on Wednesday, August 2nd. Finally, Canaccord Genuity restated a “buy” rating and set a $32.00 target price on shares of Intersect ENT in a report on Wednesday, August 2nd. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $27.70.
In other news, COO Richard E. Kaufman sold 12,500 shares of Intersect ENT stock in a transaction that occurred on Tuesday, July 25th. The shares were sold at an average price of $28.25, for a total value of $353,125.00. Following the sale, the chief operating officer now directly owns 169,821 shares in the company, valued at $4,797,443.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Richard E. Kaufman sold 22,425 shares of Intersect ENT stock in a transaction that occurred on Monday, August 28th. The shares were sold at an average price of $30.22, for a total transaction of $677,683.50. Following the completion of the sale, the chief operating officer now owns 149,821 shares in the company, valued at $4,527,590.62. The disclosure for this sale can be found here. Insiders sold 147,065 shares of company stock worth $4,345,607 over the last quarter. 13.70% of the stock is owned by corporate insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of XENT. ClariVest Asset Management LLC acquired a new stake in shares of Intersect ENT in the first quarter valued at approximately $148,000. Legal & General Group Plc raised its holdings in shares of Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after purchasing an additional 255 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its holdings in shares of Intersect ENT by 109.1% in the first quarter. Cornerstone Capital Management Holdings LLC. now owns 11,500 shares of the medical equipment provider’s stock valued at $196,000 after purchasing an additional 6,000 shares during the last quarter. Moors & Cabot Inc. acquired a new stake in shares of Intersect ENT in the second quarter valued at approximately $205,000. Finally, Prudential Financial Inc. acquired a new stake in shares of Intersect ENT in the second quarter valued at approximately $229,000. Institutional investors own 83.12% of the company’s stock.
Intersect ENT (XENT) traded up 1.46% on Monday, reaching $31.25. 102,278 shares of the company’s stock traded hands. The firm’s market cap is $912.16 million. The stock’s 50 day moving average is $30.43 and its 200 day moving average is $25.54. Intersect ENT has a 52-week low of $7.65 and a 52-week high of $33.25.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Marea Informative and is the sole property of of Marea Informative. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at http://www.mareainformativa.com/zacks-analysts-expect-intersect-ent-inc-xent-will-announce-earnings-of-0-20-per-share/117401/.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Intersect ENT Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc and related stocks with our FREE daily email newsletter.